Upgrading business potential of Enzybiotx

Since the discovery of penicillin people were living in justified confidence that available antibiotics can cure any bacterial infections.

Emerging antibiotic resistance was usually overcome by treatment with new generation of antibiotics, but during last decades bacteria are clearly winning this race.

Overuse of antibiotics, particularly in agriculture, and lack of investments in discovery of new antibiotics lead us to situation when increasing number of bacterial infections cannot be cured due to lack of effective remedy. Antibiotic resistance surveillance revealed rising antibiotic resistance around the world.

WHO predicts that if no appropriate actions are taken by 2050 antibiotic resistance will be responsible even for 10 mln deaths every year.

To address this urgent medical need new antibiotics and alternative methods of combating antibiotic resistant bacteria are needed.

One of the new approaches which is getting more and more interests among academic and industrial research groups are enzybiotics, bacteriolytic enzymes that in a very effective and selective way eliminate bacteria, including antibiotic resistant strains, at the same time displaying very low resistance prevalence.

Enzybiotx provides a deep-tech platform for tailor made-enzybiotics targeting specific bacteria.

Our company has developed the platform for design and generation of new enzybiotcs to target pathogenic bacteria of interest as an answer to the need of alternative antimicrobials development.

The company in collaboration with potential clients is able to prepare tailor-made enzybiotics which target pathogens and in collaboration with the client, perform all tests needed to adjust enzyme’s properties to be able to introduce them to the final products.

The founders of the company are experienced academics who have gathered unique expertise in isolation and characterisation of new enzybiotics.